Who is sponsoring NCT04015622?

NCT04015622 is sponsored by British Columbia Cancer Agency.

What drugs are being tested in NCT04015622?

Interventions in NCT04015622: Enzalutamide, Docetaxel.

What condition does NCT04015622 study?

NCT04015622 studies Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Is NCT04015622 still recruiting?

NCT04015622 is currently active, enrolled. Last updated 20 August 2025.

Last reviewed 2025-08-20 · How we verify

NCT04015622: PROTRACT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

Active, enrolled Phase 2 Last updated 20 August 2025

What this trial tests

Phase 2 trial testing Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

7 October 2020

Primary endpoint
1 April 2026

1 December 2026

Quick facts

Lead sponsor	British Columbia Cancer Agency
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	7 October 2020
Primary completion	1 April 2026
Estimated completion	1 December 2026
Sites	7 locations across Canada

Drugs / interventions tested

Enzalutamide (enzalutamide) — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Metastatic Castration-Resistant Prostate Cancer (mCRPC) — all drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) →

Sponsor

British Columbia Cancer Agency

Who can join

18 and older, male only, with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the strategy in treatment selection using ctDNA fraction as a predictive biomarker to direct treatment decision (ctDNA fraction \<2% receives enzalutamide, and ctDNA fraction ≥2% receives docetaxel) versus clinician's choice of enzalutamide or docetaxel, in subjects with metastatic castration-resistant prostate cancer post abiraterone setting.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
Reichert ZR, Morgan TM, Li G, Castellanos E, et al · · 2023 · cited 145× · PMID 36208697 · DOI 10.1016/j.annonc.2022.09.163
Liquid biopsy into the clinics: Current evidence and future perspectives.
Boukovala M, Westphalen CB, Probst V. · · 2024 · cited 29× · PMID 40027149 · DOI 10.1016/j.jlb.2024.100146
Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine.
Li B, Zhang Q, Castaneda C, Cook S. · · 2024 · cited 19× · PMID 39457488 · DOI 10.3390/biomedicines12102175
Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma.
Sumiyoshi T, Yamasaki T, Takeda M, Mizuno K, et al · · 2021 · cited 18× · PMID 34009695 · DOI 10.1111/cas.14972
Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
Antonarakis ES, Antonarakis ES, Tierno M, Fisher V, et al · · 2022 · cited 17× · PMID 35286728 · DOI 10.1002/pros.24331
Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer-a narrative review.
Maurice Dror C, Chi KN, Khalaf DJ. · · 2021 · cited 11× · PMID 34804836 · DOI 10.21037/tau-20-1341
Cell-free DNA in the management of prostate cancer: Current status and future prospective.
He W, Xiao Y, Yan S, Zhu Y, et al · · 2023 · cited 9× · PMID 37538150 · DOI 10.1016/j.ajur.2022.11.002
Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases.
Desai A, Pasquina LW, Nulsen C, Keller-Evans RB, et al · · 2024 · cited 5× · PMID 40027147 · DOI 10.1016/j.jlb.2024.100140

Verify or expand the search:

Other trials of Enzalutamide

Trials testing the same drug.

NCT07287150 — A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer · Phase 2 · recruiting
NCT07226986 — A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI i · Phase 1, PHASE2 · recruiting
NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
NCT07028853 — This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W · Phase 3 · recruiting
NCT06922318 — The COSMYC Trial (COmbined Suppression of MYC) · Phase 2 · recruiting

Other recruiting trials for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Currently open trials in the same condition.

NCT06004661 — Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Nor · Phase 2 · recruiting
NCT06126731 — Combination Study of Antibiotics With Enzalutamide (PROMIZE) · Phase 1, PHASE2 · recruiting
NCT06134232 — Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T · Phase 2 · recruiting
NCT05670106 — A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Pat · Phase 2 · active not recruiting
NCT05658003 — A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chine · Phase 2 · active not recruiting

Other British Columbia Cancer Agency trials

Trials by the same sponsor.

NCT07295171 — HELP Study - Towards High Throughput and Efficient Long-axial PET With Oral [18F]FDG · NA · recruiting
NCT07291895 — High Dose Radiotherapy for Palliation (Hi-D) · NA · not yet recruiting
NCT06918951 — Stereotactic Radiotherapy Versus Palliative Conventional Radiotherapy for Oligoprogressive Metastatic Cancers · NA · recruiting
NCT07210749 — Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma · NA · not yet recruiting
NCT06835725 — Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prost · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04015622 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by British Columbia Cancer Agency
Last refreshed: 20 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04015622.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing